Article Abstract

Role of immune checkpoint blockers in patients with EGFR mutation

Authors: Jeffrey Ward, Daniel Morgensztern


Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with advanced stage non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the EGFR gene, with response rates and progression-free survival (PFS) consistently better than chemotherapy (1,2). Nevertheless, despite the high initial responses, virtually all patients develop tumor progression with a median PFS of less than 12 months with first or second generation EGFR TKIs and 18.9 months with the third generation osimertinib (3). Therefore, there is a need for new therapies with more durable responses in this population of predominantly younger patients with less exposure to tobacco smoking.

Article Options

Download Citation